Anteris Technologies Global, an Australia-based maker of artificial heart valves, announced terms for its IPO on Monday.
The Toowong, Australia-based company plans to raise $100 million by offering 14.8 million shares at $6.78, the as-converted December 5 close of its shares on the ASX (AVR). At the proposed price, Anteris Technologies Global would command a market value of $244 million.
Anteris is a structural heart company focused on patients with aortic stenosis. Its lead product, the DurAVR transcatheter heart valve (THV) system, consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. To date, a total of 73 patients have been treated with the DurAVR THV system across the US, Canada, and Europe.
Anteris Technologies Global was founded in 1999 and booked $3 million in revenue for the 12 months ended September 30, 2024. It plans to list on the Nasdaq under the symbol AVR. TD Cowen, Barclays, and Cantor Fitzgerald are the joint bookrunners on the deal. It is expected to price during the week of December 9, 2024.
